

Concomitant Retrograde Coronary Venous Infusion of I Enhances Engraftment and Differentiation of Bone Mar Cardiac Repair after Myocardial Infarction

Theranostics

5, 995-1006

DOI: [10.7150/thno.11607](https://doi.org/10.7150/thno.11607)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Deficiency of <i>ATP6V1H</i> Causes Bone Loss by Inhibiting Bone Resorption and Bone Formation through the TGF- β 1 Pathway. <i>Theranostics</i> , 2016, 6, 2183-2195.	4.6	43
2	Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015). <i>Stem Cell Research and Therapy</i> , 2016, 7, 82.	2.4	163
3	Two complementary strategies to improve cell engraftment in mesenchymal stem cell-based therapy: Increasing transplanted cell resistance and increasing tissue receptivity. <i>Cell Adhesion and Migration</i> , 2017, 11, 110-119.	1.1	44
4	TNF α promotes survival and migration of MSCs under oxidative stress via NF κ B pathway to attenuate intimal hyperplasia in vein grafts. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 2077-2091.	1.6	32
5	A brief review: the therapeutic potential of bone marrow mesenchymal stem cells in myocardial infarction. <i>Stem Cell Research and Therapy</i> , 2017, 8, 242.	2.4	135
6	Progress of Stem Cell Transplantation for Treating Myocardial Infarction. <i>Current Stem Cell Research and Therapy</i> , 2017, 12, 624-636.	0.6	8
7	Retrograde Coronary Venous Infusion as a Delivery Strategy in Regenerative Cardiac Therapy: an Overview of Preclinical and Clinical Data. <i>Journal of Cardiovascular Translational Research</i> , 2018, 11, 173-181.	1.1	18
8	Cardiomyocyte differentiation of mesenchymal stem cells from bone marrow: new regulators and its implications. <i>Stem Cell Research and Therapy</i> , 2018, 9, 44.	2.4	74
9	Effects of lentiviral transfection containing bFGF gene on the biological characteristics of rabbit BMSCs. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 8389-8397.	1.2	5
10	Mesenchymal Stem Cell Migration and Tissue Repair. <i>Cells</i> , 2019, 8, 784.	1.8	526
11	Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway. <i>Life Sciences</i> , 2019, 231, 116554.	2.0	48
12	The therapeutic potential of mesenchymal stem cells for cardiovascular diseases. <i>Cell Death and Disease</i> , 2020, 11, 349.	2.7	149
13	Stem Cells in Veterinary Medicine—Current State and Treatment Options. <i>Frontiers in Veterinary Science</i> , 2020, 7, 278.	0.9	64
14	The Effect of Cardiogenic Factors on Cardiac Mesenchymal Cell Anti-Fibrogenic Paracrine Signaling and Therapeutic Performance. <i>Theranostics</i> , 2020, 10, 1514-1530.	4.6	6
15	Cardiac Differentiation of Mesenchymal Stem Cells: Impact of Biological and Chemical Inducers. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 1343-1361.	1.7	9
16	Challenges and Limitations of Strategies to Promote Therapeutic Potential of Human Mesenchymal Stem Cells for Cell-Based Cardiac Repair. <i>Korean Circulation Journal</i> , 2021, 51, 97.	0.7	17
17	Challenges of stem cell therapies in companion animal practice. <i>Journal of Veterinary Science</i> , 2020, 21, e42.	0.5	9
18	Efficacy of Stem Cell Therapy in Large Animal Models of Ischemic Cardiomyopathies: A Systematic Review and Meta-Analysis. <i>Animals</i> , 2022, 12, 749.	1.0	9

#	ARTICLE	IF	CITATIONS
19	Mesenchymal Stem Cells for Cardiac Repair. , 2022, , 1-53.		20
20	Mesenchymal Stem Cells Therapeutic Applications in Cardiovascular Disorders. , 2022, , 213-245.		0
21	Intervention effects of traditional Chinese medicine on stem cell therapy of myocardial infarction. Frontiers in Pharmacology, 0, 13, .	1.6	1
22	Mesenchymal Stem Cells for Cardiac Repair. , 2022, , 269-321.		1
23	Regenerative medicine applications: An overview of clinical trials. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	8
24	Fibrin-Enriched Cardiac Extracellular Matrix Hydrogel Promotes <i>In Vitro</i> Angiogenesis. ACS Biomaterials Science and Engineering, 2023, 9, 877-888.	2.6	2
27	Cardiovascular Stem Cell Applications in Experimental Animal Models. , 2023, , 465-490.		0
30	Hypoxia and interleukin-1-primed mesenchymal stem/stromal cells as novel therapy for stroke. Human Cell, 2024, 37, 154-166.	1.2	1